Physician profile
Landon E Dickson
NPI 1912168345
$2,055.57
in general payments reported to CMS, 2019-2025
21 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2021: $109 · 2022: $189 · 2023: $346 · 2024: $702 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Travel and Lodging: $35.51 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.89 |
| Travel and Lodging | $35.51 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $272.00 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Nxstage Medical, INC. | $270.66 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $200.89 | 2019-2023 | Farxiga, Lokelma, Evusheld |
| Otsuka America Pharmaceutical, INC. | $168.42 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $157.40 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $116.40 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $115.46 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $100.03 | 2019-2025 | |
| Novo Nordisk INC | $99.59 | 2024-2025 | Rivfloza, Rybelsus, Ozempic |
| Lilly USA, LLC | $96.40 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.74 | 2021-2024 | Jardiance |
| Ardelyx, INC. | $56.57 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $54.32 | 2019-2022 | |
| Vifor Pharma, INC. | $47.24 | 2024 | Veltassa |
| Glaxosmithkline, LLC. | $42.48 | 2021-2025 | Benlysta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $38.35 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.91 | 2023-2024 | |
| Nevro Corp. | $29.69 | 2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $28.78 | 2024 | Livtencity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | |
| Ascendis Pharma Endocrinology INC | $19.65 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Landon Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.